Morgan Stanley Reiterates Equalweight Rating on Solventum (SOLV)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
BTIG Starts Solventum (SOLV) at Neutral
September 5, 2024 5:40 AM EDTBTIG analyst Ryan Zimmerman initiates coverage on Solventum (NYSE: SOLV) with a Neutral rating.
The analyst comments "Solventum was spun out of 3M (MMM, Not Rated) in April 2024, creating a global healthcare company that operates in a variety of medical technology segments including Medical/Surgical, Dental, Health Information Systems, and Purification & Filtration with global sales of $8.2B and total addressable markets of $93B+. Historically the business segments within MMM underperformed and... More
